Scientific deep-dive
HRT, Perimenopause, and GLP-1s: Weight Management in Women After 40
Visceral fat redistribution at menopause is real (Lovejoy 2008), but a Cochrane review of 28 RCTs found HRT does not significantly change body weight. We cover the WHI trial, NAMS 2022, STEP-1 semaglutide results, and the Foundayo oral contraceptive interaction.
Weight loss in the female-majority GLP-1 obesity trials is large — STEP-1[6] reported a mean −14.9% on semaglutide 2.4 mg vs −2.4% on placebo at 68 weeks — but the menopausal metabolic shift complicates the picture for women in their 40s and 50s. Lovejoy 2008[2] documented increased visceral adipose tissue and decreased energy expenditure across the menopausal transition. The Cochrane review[5] on HRT and body weight pooled 28 RCTs (n=28,559) and concluded that HRT does NOT significantly change body weight or prevent menopausal weight gain. The 2022 NAMS hormone therapy position statement[4] sets the current framework: HRT is most beneficial for women under 60 or within 10 years of menopause, with vasomotor symptoms and bone protection as primary indications. The Foundayo (orforglipron) FDA label [8] flags a gastric-emptying interaction with oral hormonal contraceptives and advises a non-oral method or 30-day barrier contraception around initiation and dose escalations. Tirzepatide has a similar 20% reduction in oral contraceptive exposure after the 5 mg dose[9]. Here is the verified evidence.
The menopausal metabolic shift
Lovejoy 2008[2] followed 156 women (103 Caucasian, 53 African American) longitudinally across the menopausal transition for 4 years. Key findings:
- Visceral adipose tissue increased significantly with menopause onset, independent of total body weight changes
- Total body fat increased
- Resting energy expenditure decreased at menopause
- Fat oxidation decreased
The broader menopause literature documents that visceral adipose tissue rises from approximately 5-8% of total body fat in premenopausal women to 15-20% in postmenopausal women, with cumulative increases of up to 400% across the decades from early adulthood through the seventh decade. That redistribution — not just total weight gain — is what drives the metabolic risk profile shift in midlife women. Same total body weight, more central fat, worse cardiometabolic outcomes.
Kuryłowicz 2023[3] reviewed the underlying mechanism. Estrogen receptor alpha (ERα) predominates in adipocyte regulation. Estrogen modulates leptin synthesis, insulin sensitivity, and fat distribution. Premenopausal women have meaningfully greater insulin sensitivity than postmenopausal women. The metabolic shift is real and biologically grounded; it's not in your imagination.
The WHI primary findings
The Women's Health Initiative[1] remains the defining HRT trial. 16,608 healthy postmenopausal women randomized to conjugated equine estrogens 0.625 mg + medroxyprogesterone acetate 2.5 mg or placebo, mean follow-up 5.2 years until the trial was stopped early in May 2002. The primary outcomes:
- Coronary heart disease: HR 1.29 (95% CI 1.02-1.63), 286 cases
- Invasive breast cancer: HR 1.26 (95% CI 1.00-1.59), 290 cases
- Stroke: HR 1.41 (95% CI 1.07-1.85)
- Pulmonary embolism: HR 2.13 (95% CI 1.39-3.25)
- Hip fracture: HR 0.66 (95% CI 0.45-0.98) — protective
- Colorectal cancer: HR 0.63 (95% CI 0.43-0.92) — protective
Body weight was not the primary endpoint of WHI and the trial does not report large weight changes in either arm. For the body-weight-specific question, the cleaner evidence comes from the Cochrane review.
The Cochrane verdict on HRT and body weight
The Norman 2000 Cochrane systematic review[5] pooled 28 randomized trials (n=28,559) of estrogen-only and combined HRT and reported:
- Unopposed estrogen vs no HRT: mean weight difference 0.03 kg (95% CI −0.61 to 0.67) — essentially zero
- Combined estrogen + progestogen vs no HRT: mean weight difference 0.04 kg (95% CI −0.42 to 0.50) — essentially zero
- Conclusion: “HRT has no effect on body weight and cannot prevent weight gain at menopause”
This is important. Patients sometimes start HRT hoping it will help with weight; the published RCT evidence says it will not produce meaningful weight loss or weight prevention on its own. The metabolic shift at menopause is largely independent of HRT use. HRT is the right intervention for vasomotor symptoms, bone density, and possibly genitourinary symptoms; it is not a weight intervention.
NAMS 2022: who should and should not use HRT
The 2022 NAMS hormone therapy position statement [4] is the current consensus framework. The headline:
- Favorable benefit-risk: women under 60 OR within 10 years of menopause onset, without contraindications. HRT beneficial for vasomotor symptoms and bone loss prevention.
- Less favorable benefit-risk: women over 60 OR more than 10 years from menopause onset. Increased absolute risks of CHD, stroke, VTE, and dementia.
- Continuation past 60-65 is reasonable if persistent symptoms or quality-of-life benefit, with ongoing risk discussion.
- Route matters: transdermal estradiol and lower doses may carry lower VTE and stroke risk vs oral conjugated estrogens.
- Contraindications: personal history of breast or endometrial cancer, history of VTE or stroke, active liver disease, undiagnosed vaginal bleeding, uncontrolled hypertension. Migraine with aura is a relative contraindication.
For midlife women considering HRT alongside (or instead of) a GLP-1, the calculus is mostly about symptom relief and bone protection, not weight. A patient experiencing severe hot flashes, night sweats, and bone loss should consider HRT for those reasons, regardless of weight status. A patient seeking primarily weight loss should look at GLP-1s, Qsymia, or lifestyle interventions; HRT will not deliver the magnitude.
GLP-1 trial sex subgroups
STEP-1[6] enrolled 1,961 adults; across the pooled STEP 1–3 trials, 69.6% of participants were women[10]. Overall, mean weight change at week 68 was −14.9% with semaglutide 2.4 mg vs −2.4% with placebo[6]; sex-stratified results are in the trial supplement and are not reproduced here.
A 2025 meta-analysis of 14 randomized trials that reported weight change by sex (Yang 2025[12], covering dulaglutide, exenatide, liraglutide, semaglutide, and retatrutide) found that women lost more weight than men: about 1.0 kg, or 1.7 percentage points, more on average. The gap was larger in trials run for weight reduction and grew as total weight loss grew. Tirzepatide trials were not part of that analysis, and it did not test why the gap exists.
A DXA body-composition substudy of SURMOUNT-1[7] (Look 2025[11], n=160, 73% female) found that about 75% of the weight lost on tirzepatide was fat and 25% lean, proportions that held across most subgroups, including sex. Specific sex-stratified percent weight loss values are in the supplementary materials, which we could not independently confirm, so they are not reproduced here.
Magnitude comparison
Total body-weight change in midlife women — HRT alone (Cochrane pooled 28 RCTs, n=28,559) compared with FDA-approved GLP-1 medications in STEP-1 (all participants) and the female-majority SURMOUNT-1 trial.[5][6][7]
- HRT alone (Cochrane pooled RCTs, weight endpoint)0.0 % body weightZero on this scale0.03–0.04 kg difference vs no HRT — clinically null
- Semaglutide 2.4 mg (STEP-1, 68 wk, all participants)14.9 % TBWL
- Tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % TBWL
GLP-1 + HRT pharmacology
For patients on both classes:
- Transdermal estradiol bypasses the GI tract and is not affected by GLP-1-induced gastric emptying delay. This is the safest oral-route-bypass option for women on a GLP-1.
- Oral estrogen may be modestly affected by GLP-1 gastric emptying delay. Direct PK interaction studies are limited; clinical guidance from Wegovy and Ozempic labels does not flag a specific oral estrogen interaction beyond the general gastric emptying note.
- Tirzepatide (Mounjaro / Zepbound) reduces oral contraceptive exposure by approximately 20% after the 5 mg dose[9]. The label recommends barrier contraception or switching to non-oral contraception for 4 weeks after initiation and after each dose escalation. This is contraception-relevant, not HRT-relevant per se, but the same mechanism (delayed gastric emptying) applies to oral estrogen used for HRT.
- Foundayo (orforglipron) [8] is metabolized primarily via CYP3A4 and delays gastric emptying; it is the gastric-emptying delay the label cites for oral contraceptives. The label specifically advises patients on oral hormonal contraceptives to switch to non-oral methods OR add barrier contraception for 30 days after initiation and 30 days after each dose escalation. For HRT specifically, the same logic applies: prefer transdermal estradiol or vaginal estrogen, not oral.
The practical decision tree
- Vasomotor symptoms (hot flashes, night sweats) dominant: HRT is first-line. Add a GLP-1 if weight-loss is a separate goal.
- Weight gain is the primary concern: HRT will not help. GLP-1 (semaglutide, tirzepatide, or orforglipron), Qsymia, or lifestyle change are the evidence-based options.
- Bone density loss / osteoporosis prevention: HRT or bisphosphonates. GLP-1s do not preserve bone density; in fact, the rapid weight loss from GLP-1s may modestly accelerate age-related bone loss in some patients (an active research area).
- Visceral fat redistribution at menopause: GLP-1s reduce visceral fat preferentially per the STEP-1 and SURMOUNT-1 body composition substudies. Resistance training and adequate protein (see our exercise pairing article) are the key adjuncts.
- Both HRT and GLP-1 indicated: use them together. Prefer transdermal estradiol over oral estrogen to avoid the gastric emptying interaction. Use barrier contraception or non-oral methods if also on Foundayo or tirzepatide and contraception is needed.
- Premenopausal weight management on a GLP-1: if also on oral contraceptives, follow the Foundayo / tirzepatide label guidance on barrier contraception during initiation and dose escalations.
Bottom line
- Visceral fat redistribution at menopause is real (Lovejoy 2008): increased VAT, decreased energy expenditure, decreased fat oxidation.
- Cochrane review of 28 RCTs (n=28,559): HRT does NOT significantly change body weight or prevent menopausal weight gain.
- NAMS 2022 favors HRT for women under 60 or within 10 years of menopause, primarily for vasomotor symptoms and bone protection — not weight management.
- STEP-1 (mostly women): mean −14.9% body weight on semaglutide 2.4 mg vs −2.4% on placebo at 68 weeks; sex-stratified results are in the trial supplement.
- Foundayo gastric-emptying interaction with oral hormonal contraceptives: non-oral method or 30-day barrier contraception recommended after initiation and each dose escalation.
- Tirzepatide: 20% reduction in oral contraceptive exposure after the 5 mg dose; same 4-week barrier guidance.
- For women on both HRT and a GLP-1: prefer transdermal estradiol or vaginal estrogen to avoid the gastric emptying interaction; the combination is otherwise safe and complementary.
Decisions about hormone therapy, including initiation, formulation, dose, route, and duration, should be made with a clinician familiar with the individual's medical history, family history of breast or endometrial cancer, cardiovascular risk profile, and personal preferences. NAMS 2022 guidance is the current US consensus framework.
Frequently Asked Questions
References
- 1.Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002. PMID: 12117397.
- 2.Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008. PMID: 18332882.
- 3.Kuryłowicz A. Estrogens in adipose tissue physiology and obesity-related dysfunction. Biomedicines. 2023. PMID: 36979669.
- 4.Faubion SS, Crandall CJ, Davis L, El Khoudary SR, Hodis HN, Lobo RA, Maki PM, Manson JE, Pinkerton JV, Santoro NF, Shifren JL, Shufelt CL, Thurston RC, Wolfman WL. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022. PMID: 35797481.
- 5.Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev. 2000. https://www.cochrane.org/CD001018/MENSTR_hormone-replacement-therapy-has-no-effect-on-body-weight-and-cannot-prevent-weight-gain-at-menopause
- 6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 7.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
- 8.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information including CYP3A4 metabolism, oral hormonal contraceptive interaction, and 30-day barrier contraception recommendation. FDA DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 9.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 7 Drug Interactions including 20% reduction in oral contraceptive exposure after 5 mg dose. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
- 10.Wadden TA, Brown GK, Egebjerg C, Frenkel O, Goldman B, Kushner RF, et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024. PMID: 39226070.
- 11.Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, Stefanski A, Griffin R. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
- 12.Yang Y, He L, Han S, Yang N, Liu Y, et al. Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. J Diabetes. 2025. PMID: 40040445.
Related research
Menopause Belly Fat: Why It Happens and What Actually Shrinks It
Menopause belly is mostly fat shifting to the waist plus muscle loss, not big weight gain. What SWAN and meta-analyses show about the cause, how to tell fat from bloating, and what shrinks it: diet, exercise, protein, sleep, alcohol, HRT and GLP-1s.
10 min read
DVT and Blood Clots with Obesity: Estrogen, Surgery and What GLP-1 Data Show
Deep vein thrombosis and pulmonary embolism symptoms, how obesity raises clot risk and multiplies the risk from the pill and oral HRT, the surgical window, what weight loss changes, and the conflicting trial and real-world evidence on GLP-1 drugs and blood clots.
11 min read
Breast Changes After GLP-1 Weight Loss
Breasts are mostly fat, so GLP-1 weight loss shrinks them and can cause sagging. What helps, what can't, bra size, surgery, and when to see a doctor.
11 min read
Does Ozempic Affect Your Sex Drive? The Honest Both-Ways Answer
There's no proven direct GLP-1 effect on libido. Ozempic and sex drive changes are indirect and go both ways - via weight loss, testosterone, mood, and energy.
11 min read
GLP-1 for Endometriosis: Pain, Inflammation, Weight Evidence
Endometriosis affects an estimated 10-15% of reproductive-age women. GLP-1 receptor agonists lower systemic inflammatory markers in type 2 diabetes trials, but no completed trial has tested them for endometriosis pain. We review the mechanistic and early clinical data.
11 min read
GLP-1s for PCOS: Off-Label Evidence, Trial Data & Insurance Coverage (2026)
GLP-1s are off-label for PCOS, but a 2024 meta-analysis found BMI fell 2.42 points and testosterone 1.33 nmol/L, and one series restored 80% of cycles. Cigna lists PCOS as a qualifying condition; here is the PA strategy.
13 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Pricing Compare
Get started →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →Pricing Compare
Get started →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Read full review →Pricing Compare
Get started →